331 related articles for article (PubMed ID: 31441045)
1. Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemia.
Aldoss I; Zhang J; Pillai R; Shouse G; Sanchez JF; Mei M; Nakamura R; Stein AS; Forman SJ; Marcucci G; Pullarkat V
Br J Haematol; 2019 Oct; 187(2):e45-e48. PubMed ID: 31441045
[No Abstract] [Full Text] [Related]
2. Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable-risk acute myeloid leukemia.
Arslan S; Zhang J; Dhakal P; Moran J; Naidoo N; Lombardi J; Pullarkat V; Stein AS; Marcucci G; Yaghmour G; Bhatt VR; Fathi AT; Aldoss I
Am J Hematol; 2021 Mar; 96(3):E59-E63. PubMed ID: 33227142
[No Abstract] [Full Text] [Related]
3. Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).
Badar T; Nanaa A; Atallah E; Shallis RM; Guilherme SCC; Goldberg AD; Saliba AN; Patel A; Bewersdorf JP; DuVall AS; Bradshaw D; Abaza Y; Murthy GSG; Palmisiano N; Zeidan AM; Kota V; Litzow MR
Blood Cancer J; 2024 Feb; 14(1):32. PubMed ID: 38378617
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax.
Kim K; Maiti A; Loghavi S; Pourebrahim R; Kadia TM; Rausch CR; Furudate K; Daver NG; Alvarado Y; Ohanian M; Sasaki K; Short NJ; Takahashi K; Yilmaz M; Tang G; Ravandi F; Kantarjian HM; DiNardo CD; Konopleva MY
Cancer; 2021 Oct; 127(20):3772-3781. PubMed ID: 34255353
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.
Aldoss I; Yang D; Aribi A; Ali H; Sandhu K; Al Malki MM; Mei M; Salhotra A; Khaled S; Nakamura R; Snyder D; O'Donnell M; Stein AS; Forman SJ; Marcucci G; Pullarkat V
Haematologica; 2018 Sep; 103(9):e404-e407. PubMed ID: 29545346
[No Abstract] [Full Text] [Related]
6. Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Cluzeau T; Loschi M; Fenaux P; Komrokji R; Sallman DA
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576266
[TBL] [Abstract][Full Text] [Related]
7. Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia.
Venugopal S; Maiti A; DiNardo CD; Loghavi S; Daver NG; Kadia TM; Rausch CR; Alvarado Y; Ohanian M; Sasaki K; Short NJ; Takahashi K; Yilmaz M; Ravandi F; Kantarjian HM; Konopleva MY
Am J Hematol; 2021 May; 96(5):E154-E157. PubMed ID: 33580980
[No Abstract] [Full Text] [Related]
8. Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.
Aldoss I; Yang D; Pillai R; Sanchez JF; Mei M; Aribi A; Ali H; Sandhu K; Al Malki MM; Salhotra A; Khaled S; Sun W; O'Donnell M; Snyder D; Nakamura R; Stein AS; Forman SJ; Marcucci G; Pullarkat V
Am J Hematol; 2019 Oct; 94(10):E253-E255. PubMed ID: 31259427
[No Abstract] [Full Text] [Related]
9. Hypomethylating agents and venetoclax in acute myeloid leukemia.
DiNardo CD
Clin Adv Hematol Oncol; 2021 Feb; 19(2):82-83. PubMed ID: 33596188
[No Abstract] [Full Text] [Related]
10. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
11. Rebound thrombocytosis is associated with response in AML patients treated with venetoclax and hypomethylating agents.
Othman TA; Mei M; Zhang J; Aldoss I; Stein A; Forman SJ; Marcucci G; Pullarkat V
Am J Hematol; 2021 May; 96(5):E140-E143. PubMed ID: 33524204
[No Abstract] [Full Text] [Related]
12. The feasibility of venetoclax and decitabine in therapy-related acute myeloid leukemia with concurrent advanced non-hematological malignancies.
Otoukesh S; Salhotra A; Marcucci G; Forman SJ; Pullarkat V; Aldoss I
Leuk Res; 2019 Sep; 84():106196. PubMed ID: 31377457
[No Abstract] [Full Text] [Related]
13. Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax.
Wang YW; Tsai CH; Lin CC; Tien FM; Chen YW; Lin HY; Yao M; Lin YC; Lin CT; Cheng CL; Tang JL; Chou WC; Hou HA; Tien HF
Ann Hematol; 2020 Mar; 99(3):501-511. PubMed ID: 31965269
[TBL] [Abstract][Full Text] [Related]
14. Venetoclax with decitabine or azacitidine for AML.
Das M
Lancet Oncol; 2018 Dec; 19(12):e672. PubMed ID: 30392809
[No Abstract] [Full Text] [Related]
15. Venetoclax plus decitabine induced complete remission with molecular response in acute myeloid leukemia relapsed after hematopoietic stem cell transplantation.
Andreani G; Dragani M; Serra A; Nicoli P; De Gobbi M; Cilloni D
Am J Hematol; 2019 Feb; 94(2):E48-E50. PubMed ID: 30431666
[No Abstract] [Full Text] [Related]
16. Venetoclax-induced tumour lysis syndrome in acute myeloid leukaemia.
Esparza S; Muluneh B; Galeotti J; Matson M; Richardson DR; Montgomery ND; Coombs CC; Jamieson K; Foster MC; Zeidner JF
Br J Haematol; 2020 Jan; 188(1):173-177. PubMed ID: 31621058
[No Abstract] [Full Text] [Related]
17. Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy.
Venugopal S; Shoukier M; Konopleva M; Dinardo CD; Ravandi F; Short NJ; Andreeff M; Borthakur G; Daver N; Pemmaraju N; Sasaki K; Montalban-Bravo G; Marx KR; Pierce S; Popat UR; Shpall EJ; Kanagal-Shamanna R; Garcia-Manero G; Kantarjian HM; Kadia TM
Cancer; 2021 Oct; 127(19):3541-3551. PubMed ID: 34182597
[TBL] [Abstract][Full Text] [Related]
18. Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia.
Tiong IS; Dillon R; Ivey A; Teh TC; Nguyen P; Cummings N; Taussig DC; Latif AL; Potter NE; Runglall M; Russell NH; Raj K; Schwarer AP; Fong CY; Grigg AP; Wei AH
Br J Haematol; 2021 Mar; 192(6):1026-1030. PubMed ID: 32458446
[TBL] [Abstract][Full Text] [Related]
19. Risk of tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax-containing regimens without dose ramp-up.
Shahswar R; Beutel G; Gabdoulline R; Koenecke C; Markel D; Eder M; Stadler M; Gohring G; Schlegelberger B; Trummer A; Krauter J; Thol F; Heuser M
Ann Hematol; 2021 Feb; 100(2):595-599. PubMed ID: 32705308
[No Abstract] [Full Text] [Related]
20. Venetoclax and hypomethylating agent combination therapy in acute myeloid leukemia secondary to a myeloproliferative neoplasm.
Tremblay D; Feld J; Dougherty M; Czaplinska T; Sanchez G; Kremyanskaya M; Bar-Natan M; Shih AH; Keyzner A; Mascarenhas J
Leuk Res; 2020 Nov; 98():106456. PubMed ID: 33002673
[No Abstract] [Full Text] [Related]
[Next] [New Search]